These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 20549828)
1. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cohen V; Agulnik JS; Jarry J; Batist G; Small D; Kreisman H; Tejada NA; Miller WH; Chong G Cancer; 2006 Dec; 107(12):2858-65. PubMed ID: 17096434 [TBL] [Abstract][Full Text] [Related]
3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Jänne PA; Johnson BE Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820 [TBL] [Abstract][Full Text] [Related]
4. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572 [TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039 [TBL] [Abstract][Full Text] [Related]
8. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959 [TBL] [Abstract][Full Text] [Related]
9. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251 [TBL] [Abstract][Full Text] [Related]
10. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183 [TBL] [Abstract][Full Text] [Related]
11. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159 [TBL] [Abstract][Full Text] [Related]
12. Detection of low-level EGFR T790M mutation in lung cancer tissues. Oh JE; An CH; Yoo NJ; Lee SH APMIS; 2011 Jul; 119(7):403-11. PubMed ID: 21635547 [TBL] [Abstract][Full Text] [Related]
13. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302 [TBL] [Abstract][Full Text] [Related]
14. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613 [TBL] [Abstract][Full Text] [Related]
17. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614 [TBL] [Abstract][Full Text] [Related]
18. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658 [TBL] [Abstract][Full Text] [Related]
19. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350 [TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. McMillen E; Ye F; Li G; Wu Y; Yin G; Liu W Exp Lung Res; 2010 Nov; 36(9):531-7. PubMed ID: 20939760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]